142 related articles for article (PubMed ID: 18619714)
1. A novel QSAR model for predicting the inhibition of CXCR3 receptor by 4-N-aryl-[1,4] diazepane ureas.
Afantitis A; Melagraki G; Sarimveis H; Igglessi-Markopoulou O; Kollias G
Eur J Med Chem; 2009 Feb; 44(2):877-84. PubMed ID: 18619714
[TBL] [Abstract][Full Text] [Related]
2. QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors.
Ravichandran V; Shalini S; Sundram K; Sokkalingam AD
Eur J Med Chem; 2010 Jul; 45(7):2791-7. PubMed ID: 20347187
[TBL] [Abstract][Full Text] [Related]
3. Identification and initial evaluation of 4-N-aryl-[1,4]diazepane ureas as potent CXCR3 antagonists.
Cole AG; Stroke IL; Brescia MR; Simhadri S; Zhang JJ; Hussain Z; Snider M; Haskell C; Ribeiro S; Appell KC; Henderson I; Webb ML
Bioorg Med Chem Lett; 2006 Jan; 16(1):200-3. PubMed ID: 16213722
[TBL] [Abstract][Full Text] [Related]
4. Quantitative structure-activity relationship (QSAR) study of interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor activity by the genetic algorithm and multiple linear regression (GA-MLR) method.
Pourbasheer E; Riahi S; Ganjali MR; Norouzi P
J Enzyme Inhib Med Chem; 2010 Dec; 25(6):844-53. PubMed ID: 20429783
[TBL] [Abstract][Full Text] [Related]
5. Prediction of CCR5 receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas based on the heuristic method, support vector machine and projection pursuit regression.
Yuan Y; Zhang R; Hu R; Ruan X
Eur J Med Chem; 2009 Jan; 44(1):25-34. PubMed ID: 18433938
[TBL] [Abstract][Full Text] [Related]
6. Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives.
Watson RJ; Allen DR; Birch HL; Chapman GA; Galvin FC; Jopling LA; Knight RL; Meier D; Oliver K; Meissner JW; Owen DA; Thomas EJ; Tremayne N; Williams SC
Bioorg Med Chem Lett; 2008 Jan; 18(1):147-51. PubMed ID: 18032038
[TBL] [Abstract][Full Text] [Related]
7. Quantitative structure-activity relationship and classification analysis of diaryl ureas against vascular endothelial growth factor receptor-2 kinase using linear and non-linear models.
Sun M; Chen J; Wei H; Yin S; Yang Y; Ji M
Chem Biol Drug Des; 2009 Jun; 73(6):644-54. PubMed ID: 19635056
[TBL] [Abstract][Full Text] [Related]
8. Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.
Wang Y; Busch-Petersen J; Wang F; Kiesow TJ; Graybill TL; Jin J; Yang Z; Foley JJ; Hunsberger GE; Schmidt DB; Sarau HM; Capper-Spudich EA; Wu Z; Fisher LS; McQueney MS; Rivero RA; Widdowson KL
Bioorg Med Chem Lett; 2009 Jan; 19(1):114-8. PubMed ID: 19014886
[TBL] [Abstract][Full Text] [Related]
9. Comparative QSAR modeling of CCR5 receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas.
Thomas Leonard J; Roy K
Bioorg Med Chem Lett; 2006 Sep; 16(17):4467-74. PubMed ID: 16806923
[TBL] [Abstract][Full Text] [Related]
10. Quantitative structure-activity relationship studies on 1-aryl-tetrahydroisoquinoline analogs as active anti-HIV agents.
Chen KX; Xie HY; Li ZG; Gao JR
Bioorg Med Chem Lett; 2008 Oct; 18(20):5381-6. PubMed ID: 18835162
[TBL] [Abstract][Full Text] [Related]
11. A combined LS-SVM & MLR QSAR workflow for predicting the inhibition of CXCR3 receptor by quinazolinone analogs.
Afantitis A; Melagraki G; Sarimveis H; Koutentis PA; Igglessi-Markopoulou O; Kollias G
Mol Divers; 2010 May; 14(2):225-35. PubMed ID: 19484370
[TBL] [Abstract][Full Text] [Related]
12. Adaptive neuro-fuzzy inference system (ANFIS): a new approach to predictive modeling in QSAR applications: a study of neuro-fuzzy modeling of PCP-based NMDA receptor antagonists.
Buyukbingol E; Sisman A; Akyildiz M; Alparslan FN; Adejare A
Bioorg Med Chem; 2007 Jun; 15(12):4265-82. PubMed ID: 17434739
[TBL] [Abstract][Full Text] [Related]
13. Design and optimization of imidazole derivatives as potent CXCR3 antagonists.
Du X; Chen X; Mihalic JT; Deignan J; Duquette J; Li AR; Lemon B; Ma J; Miao S; Ebsworth K; Sullivan TJ; Tonn G; Collins TL; Medina JC
Bioorg Med Chem Lett; 2008 Jan; 18(2):608-13. PubMed ID: 18063364
[TBL] [Abstract][Full Text] [Related]
14. Novel CXCR3 antagonists with a piperazinyl-piperidine core.
McGuinness BF; Carroll CD; Zawacki LG; Dong G; Yang C; Hobbs DW; Jacob-Samuel B; Hall JW; Jenh CH; Kozlowski JA; Anilkumar GN; Rosenblum SB
Bioorg Med Chem Lett; 2009 Sep; 19(17):5205-8. PubMed ID: 19647429
[TBL] [Abstract][Full Text] [Related]
15. Development of CXCR3 antagonists. Part 2: Identification of 2-amino(4-piperidinyl)azoles as potent CXCR3 antagonists.
Watson RJ; Allen DR; Birch HL; Chapman GA; Hannah DR; Knight RL; Meissner JW; Owen DA; Thomas EJ
Bioorg Med Chem Lett; 2007 Dec; 17(24):6806-10. PubMed ID: 17964154
[TBL] [Abstract][Full Text] [Related]
16. A QSAR study using MTD method and Dragon descriptors for a series of selective ligands of α2C adrenoceptor.
Borota A; Mracec M; Gruia A; Rad-Curpăn R; Ostopovici-Halip L; Mracec M
Eur J Med Chem; 2011 Mar; 46(3):877-84. PubMed ID: 21277656
[TBL] [Abstract][Full Text] [Related]
17. Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.
Thoma G; Baenteli R; Lewis I; Wagner T; Oberer L; Blum W; Glickman F; Streiff MB; Zerwes HG
Bioorg Med Chem Lett; 2009 Nov; 19(21):6185-8. PubMed ID: 19783143
[TBL] [Abstract][Full Text] [Related]
18. Exploring QSAR for substituted 2-sulfonyl-phenyl-indol derivatives as potent and selective COX-2 inhibitors using different chemometrics tools.
Khoshneviszadeh M; Edraki N; Miri R; Hemmateenejad B
Chem Biol Drug Des; 2008 Dec; 72(6):564-74. PubMed ID: 19090923
[TBL] [Abstract][Full Text] [Related]
19. Validated quantitative structure-activity relationship analysis of a series of 2-aminothiazole based p56(Lck) inhibitors.
Li J; Du J; Xi L; Liu H; Yao X; Liu M
Anal Chim Acta; 2009 Jan; 631(1):29-39. PubMed ID: 19046675
[TBL] [Abstract][Full Text] [Related]
20. Towards small-molecule CXCR3 ligands with clinical potential.
Wijtmans M; Verzijl D; Leurs R; de Esch IJ; Smit MJ
ChemMedChem; 2008 Jun; 3(6):861-72. PubMed ID: 18442035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
